Improvement in health status with once-daily indacaterol/glycopyrronium 110/50 μg in COPD patients: real-world evidence from an observational study in Ireland

Aims Indacaterol/glycopyrronium (IND/GLY) 110/50 μg is a once-daily (o.d.) fixed-dose combination of long-acting β 2 -agonist/long-acting muscarinic antagonist approved in over 90 countries, including Ireland, for the management of COPD. The present study was conducted to evaluate health status of C...

Full description

Saved in:
Bibliographic Details
Published in:Irish journal of medical science 2019-11, Vol.188 (4), p.1251-1259
Main Authors: O’Doherty, Brian, Dorman, Jane, McGrath, Karen, Kelly, Kevin, Molony, David, Lacey, Seán, Whelan, Sarah, Schmid, Simon, Sullivan, Shane
Format: Article
Language:English
Subjects:
Adrenergic beta-2 Receptor Agonists - administration & dosage
Adult
Aged
Aged, 80 and over
Bronchodilator Agents - administration & dosage
Family Medicine
Female
General Practice
Glycopyrrolate - administration & dosage
Health Status
Humans
Indans - administration & dosage
Internal Medicine
Ireland
Male
Medicine
Medicine & Public Health
Middle Aged
Muscarinic Antagonists - administration & dosage
Original Article
Prospective Studies
Pulmonary Disease, Chronic Obstructive - drug therapy
Quinolones - administration & dosage
Severity of Illness Index
Surveys and Questionnaires
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims Indacaterol/glycopyrronium (IND/GLY) 110/50 μg is a once-daily (o.d.) fixed-dose combination of long-acting β 2 -agonist/long-acting muscarinic antagonist approved in over 90 countries, including Ireland, for the management of COPD. The present study was conducted to evaluate health status of COPD patients, initiated on IND/GLY 110/50 μg o.d., using the Clinical COPD Questionnaire (CCQ) tool in a real-world primary care setting in Ireland. Methods This was a real-world, prospective, open-label study. COPD patients aged > 40 years and with a smoking history of > 10 pack-years were included and switched to once-daily IND/GLY 110/50 μg. Enrolment of patients into the study occurred only after the decision had been made by the physician to prescribe IND/GLY 110/50 μg. Data were collected at baseline and Week 26. Health status was assessed using the validated CCQ. Results A total of 200 patients were included in study. The mean CCQ total score decreased from 2.36 at baseline to 1.44 at Week 26 (Δ, 0.92; P  
ISSN:0021-1265
1863-4362
DOI:10.1007/s11845-019-02001-y